Tyra Biosciences, Inc. Stock Price, News & Analysis

Tyra Biosciences (Nasdaq: TYRA) reported Q3 2025 results and clinical progress on November 5, 2025. Key clinical updates: TYRA dosed first patients with dabogratinib in BEACH301 (achondroplasia) and SURF302 (FGFR3-altered IR NMIBC), advanced development into LG-UTUC with an IND cleared by the FDA, and expects interim Phase 2 readouts in 2026.

Financials: TYRA held $274.9 million in cash, cash equivalents and marketable securities as of September 30, 2025, providing runway through at least 2027. Q3 R&D was $25.5M, G&A $7.5M, and net loss $29.9M.

Tyra Biosciences (Nasdaq: TYRA) has announced a significant milestone in its BEACH301 Phase 2 clinical study, with the first child being dosed with dabogratinib (TYRA-300) for treating achondroplasia, the most common form of dwarfism.

Dabogratinib is positioned as the only oral FGFR3-selective inhibitor in clinical development for achondroplasia, which affects approximately 250,000 individuals worldwide. The drug targets the FGFR3 G380R mutation, present in 99% of achondroplasia cases. Initial results from the safety sentinel cohort are expected in 2H 2026.

The study aims to evaluate the safety and efficacy of this once-daily oral treatment, developed using TYRA's proprietary SNÅP platform, offering a potentially more accessible treatment option for children with achondroplasia.

Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotech company specializing in Fibroblast Growth Factor Receptor (FGFR) precision medicines, has announced its participation in two upcoming investor events.

The company will participate in a fireside chat at the Virtual H.C. Wainwright "HCW@Home" series on August 21, 2025, at 11 AM ET. Additionally, management will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9 AM ET in New York, featuring a fireside chat and one-on-one investor meetings.

Webcasts of both events will be accessible through Tyra's investor relations website.

Tyra Biosciences (NASDAQ: TYRA) reported Q2 2025 financial results and significant progress in its clinical programs. The company maintains a strong financial position with $296.3 million in cash and equivalents, providing runway through 2027. Key developments include dosing the first patient in SURF302, a Phase 2 study evaluating dabogratinib for intermediate-risk non-muscle invasive bladder cancer (IR NMIBC).

The company reported a net loss of $28.1 million for Q2 2025, with R&D expenses of $24.3 million and G&A expenses of $7.1 million. TYRA is advancing multiple clinical programs, including BEACH301 for achondroplasia, SURF431 for hepatocellular carcinoma, and SURF201 for intrahepatic cholangiocarcinoma. Important upcoming milestone includes topline data from SURF302 expected in 1H 2026.

Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotech company specializing in Fibroblast Growth Factor Receptor (FGFR) precision medicines, has announced its participation in a virtual fireside chat at the UBS Biotech Management Live Call Series.

The event, focused on achondroplasia and growth disorders, will take place on July 25, 2025, at 11 am ET. Key participants include CEO Todd Harris, CMO Doug Warner, MD, and CFO Alan Fuhrman, with UBS SMID Cap Biotechnology Analyst Ellie Merle hosting the discussion.

Tyra Biosciences (Nasdaq: TYRA) has announced that its late-breaking abstract about TYRA-300 has been accepted for presentation at ENDO 2025, scheduled for July 12-15, 2025 in San Francisco. The poster presentation, titled "TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia," will be presented by Dr. Jacqueline H. Starrett on July 13, 2025.

The presentation will be part of Session P70, focusing on bone and mineral metabolism, specifically rare bone and genetic disorders. The poster will be available on Tyra's investor relations website following the conference.

Tyra Biosciences (Nasdaq: TYRA) has initiated patient dosing in the Phase 2 SURF302 clinical trial of TYRA-300 for low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC). TYRA-300 is being developed as the first oral treatment for IR NMIBC and represents a potential first-in-class, FGFR3-selective inhibitor.

The SURF302 study (NCT06995677) will evaluate up to 90 participants across multiple U.S. sites, with patients randomized to receive either 50 mg or 60 mg once-daily doses. The trial's primary endpoint is the complete response (CR) rate at three months, with initial data expected in 1H 2026. Secondary endpoints include time to recurrence, duration of response, recurrence-free survival, progression-free survival, and safety measures.

Notably, TYRA-300 targets FGFR3, a gene mutated in approximately 70% of low-grade IR NMIBC cases. The drug is designed to minimize toxicities associated with inhibition of other FGFR types while remaining effective against FGFR3 gatekeeper mutations. The company also plans to evaluate TYRA-300 in pediatric achondroplasia through the BEACH301 Phase 2 study later this year.

[ "First patient dosed in Phase 2 SURF302 trial for IR NMIBC", "TYRA-300 is the only oral treatment in development for IR NMIBC", "Drug targets FGFR3 mutations present in ~70% of low-grade IR NMIBC cases", "Potential to reduce disease recurrence and surgical interventions", "Additional market opportunity in pediatric achondroplasia with BEACH301 Phase 2 study" ]

Tyra Biosciences (NASDAQ: TYRA), a clinical-stage biotech company specializing in FGFR-targeted precision medicines, has announced its participation in three upcoming investor conferences. The company will attend the Bank of America Global Healthcare Conference (May 13-15) in Las Vegas, featuring a fireside chat on May 13 at 5:15 PM PT. Additionally, TYRA will participate in the Jefferies Global Healthcare Conference (June 3-5) and UBS Biotech 1x1 Symposium (June 24) in New York, both featuring one-on-one investor meetings. A webcast of the fireside chat will be accessible through TYRA's investor relations website.

Tyra Biosciences (NASDAQ: TYRA) reported Q1 2025 financial results and corporate updates. The company has $318.9 million in cash and equivalents, providing runway through 2027. Key developments include: 1) Advancement of TYRA-300: - BEACH301 study for pediatric achondroplasia now enrolling - SURF302 Phase 2 study for bladder cancer preparing to start - Published positive preclinical results in JCI Insight 2) Progress with other programs: - TYRA-200: Continuing Phase 1 SURF201 study for cholangiocarcinoma - TYRA-430: Initiated patient dosing in SURF431 study for liver cancer Financial highlights show Q1 2025 net loss of $28.1 million vs $18.2 million in Q1 2024. R&D expenses increased to $25.0 million from $17.2 million, while G&A expenses rose to $6.9 million from $5.1 million.